Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2018 - 2026)
Phathom Pharmaceuticals' (PHAT) quarterly Income from Continuing Operations came in at 47971000.0 in Q1 2026, up 49.13% year-on-year from 32168069.82 in Q1 2025, and down 126.89% on a QoQ basis from 21143000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Income from Continuing Operations data on file, last reported at 47971000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 49.13% year-over-year to 47971000.0 in Q1 2026; TTM through Mar 2026 was 207742000.0, a 45.18% increase from a year earlier, with the FY2025 full-year figure at 233451000.0, up 54.9% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 47971000.0, down from 21143000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PHAT reached as high as 21143000.0 in Q4 2025 and fell as low as 118690000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 64045235.29 across 5 years, with a median of 51080000.0 in 2022.
- Across the five-year window, Income from Continuing Operations plunged 175.73% in 2024 and soared 71.62% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 49155000.0 in 2022, then tumbled by 103.99% to 100273000.0 in 2023, then rose by 25.7% to 74500000.0 in 2024, then surged by 71.62% to 21143000.0 in 2025, then plunged by 126.89% to 47971000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 47971000.0 in Q1 2026, 21143000.0 in Q4 2025, and 55212000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Phathom Pharmaceuticals | 945.22 Mn | 761.46 Mn | 46.31 Mn | -47.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.97 Mn |
| Dec 31, 2025 | -21.14 Mn |
| Sep 30, 2025 | -55.21 Mn |
| Jun 30, 2025 | -83.42 Mn |
| Mar 31, 2025 | -94.29 Mn |
| Dec 31, 2024 | -74.50 Mn |
| Sep 30, 2024 | -118.69 Mn |
| Jun 30, 2024 | -91.44 Mn |
| Mar 31, 2024 | -82.81 Mn |
| Dec 31, 2023 | -100.27 Mn |
| Sep 30, 2023 | -43.05 Mn |
| Jun 30, 2023 | -46.29 Mn |
| Mar 31, 2023 | -37.83 Mn |
| Dec 31, 2022 | -49.16 Mn |
| Sep 30, 2022 | -51.08 Mn |
| Jun 30, 2022 | -50.92 Mn |
| Mar 31, 2022 | -40.70 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -63.72 Mn |
| Jun 30, 2021 | -69.91 Mn |